证券代码：688158 证券简称：优刻得 优刻得科技股份有限公司 2025 年第一次临时股东会 会议资料 2025 年 10 月 | | | | 会议须知 | 1 | | --- | --- | | 会议议程 | 3 | | 会议议案 | 5 | | 议案一：关于公司取消监事会暨修订《公司章程》的议案 | 5 | | 议案二：关于制定及修订公司部分治理制度的议案 | 6 | | 议案三：关于以集中竞价交易方式回购公司股份方案的议案 | 35 | | 议案四：关于《公司 2025 年限制性股票激励计划（草案）》及其摘要的议案 | .. 37 | | 议案五：关于《公司 2025 年限制性股票激励计划实施考核管理办法》的议案 | .. 38 | | 议案六：关于提请股东会授权董事会办理公司 2025 | 年限制性股票激励计划有关事 | | 项的议案 | 39 | 优刻得科技股份有限公司 2025 年第一次临时股东会 会议须知 一、为确认出席股东会的股东或其代理人或其他出席者的出席资格，会议工 作人员将对出席会议者的身份进行必要的核对工作，请被核对者给予配合。 二、为保证本次股东会的严肃性和正常秩序，切实维护股东的 ...

证券代码：688158 证券简称：优刻得 公告编号：2025-043 优刻得科技股份有限公司 监事会关于公司 2025 年限制性股票激励计划 首次授予激励对象名单的公示情况说明及核查意见 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 优刻得科技股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日召开了第三届 董事会第六次会议、第三届监事会第六次会议，审议通过了《关于公司< 2025 年限制 性股票激励计划（草案）>及其摘要的议案》等相关议案。根据《上市公司股权激励管 理办法》（以下简称"《管理办法》"）的相关规定，公司对 2025 年限制性股票激励 计划拟首次授予激励对象名单在公司内部进行了公示，公司监事会结合公示情况对拟 激励对象进行了核查，相关公示情况及核查情况如下： 一、公示情况及核查方式 1、公示情况 公司于 2025 年 9 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《优刻 得科技股份有限公司 2025 年限制性股票激励计划（草案）》（以下简称 "《激励计划 （草案）》 ...

一、公示情况及核查方式 1、公示情况 公司于 2025 年 9 月 30 日在上海证券交易所网站（www.sse.com.cn）披露了《优刻 得科技股份有限公司 2025 年限制性股票激励计划（草案）》（以下简称 "《激励计划 （草案）》）"及其摘要、《优刻得科技股份有限公司 2025 年限制性股票激励计划首 次授予激励对象名单》等文件，并于 2025 年 9 月 30 日至 2025 年 10 月 9 日在公司内部 对本次拟激励对象的姓名和职务进行了公示，公示期间公司员工可向公司董事会薪酬 与考核委员会提出意见。 证券代码：688158 证券简称：优刻得 公告编号：2025-042 优刻得科技股份有限公司董事会 薪酬与考核委员会关于公司 2025 年限制性股票激励计划 首次授予激励对象名单的公示情况说明及核查意见 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或 者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 优刻得科技股份有限公司（以下简称"公司"）于 2025 年 9 月 29 日召开了第三届 董事会第六次会议、第三届监事会第六次会议，审议通过了《关于公司< 202 ...

Group 1 - Double-Helix Pharmaceutical announced that its associate, Changfeng Pharmaceutical, is expected to be listed on the Hong Kong Stock Exchange on October 8, 2025, with a global offering of 41.198 million shares priced at HKD 14.75 each. Double-Helix holds approximately 3.68% of Changfeng's shares, with a lock-up period of 12 months post-listing [1] - Changfeng Pharmaceutical is involved in the pharmaceutical industry, specifically in the research and development of gene-engineered drugs [2] Group 2 - Lio Corporation has submitted an application to the Hong Kong Stock Exchange for issuing H-shares and listing on the main board [3] - Lio Corporation operates in the mechanical manufacturing and digital marketing sectors [3] Group 3 - Changjiang Securities received approval from the China Securities Regulatory Commission to issue corporate bonds totaling no more than CNY 20 billion, valid for 24 months [4] - Changjiang Securities provides services such as securities and futures brokerage, financial product distribution, investment advisory, asset custody, and margin financing [4] Group 4 - Jingye Intelligent plans to acquire 51% of Hefei Shengwen Information Technology for CNY 108 million, focusing on engineering information technology and intelligent products [5][6] - Jingye Intelligent specializes in the research, development, production, and sales of special robots and intelligent equipment systems [6] Group 5 - Aimeike's subsidiary received approval for the registration of Minoxidil topical solution, a non-prescription drug for treating hair loss [7][8] - Aimeike is engaged in the research, development, production, and sales of biomedical materials and biopharmaceuticals [8] Group 6 - Dalian Heavy Industry expects a net profit of CNY 474 million to CNY 508 million for the first three quarters of 2025, representing a year-on-year increase of 19.91% to 28.52% [9] - Dalian Heavy Industry specializes in the design, manufacturing, assembly, and installation of major technical equipment [9] Group 7 - Huayou Cobalt signed supply agreements with LGES for a total of approximately 76,000 tons of ternary precursor products from 2026 to 2030 [10][11] - Huayou Cobalt focuses on the research, manufacturing, and sales of new energy lithium battery materials and cobalt new materials [11] Group 8 - Zhenjiang Co. plans to reduce its shareholding by up to 5.529 million shares, not exceeding 3% of the total share capital, due to personal funding needs [12] - Zhenjiang Co. is involved in the design, processing, and sales of wind power equipment and components [12] Group 9 - Watson Bio's subsidiary received a drug registration certificate for a 13-valent pneumococcal polysaccharide conjugate vaccine for children [14][15] - Watson Bio specializes in the research, development, production, and sales of human vaccines and biopharmaceuticals [15] Group 10 - Yikang Pharmaceutical's major shareholder plans to reduce holdings by up to 42 million shares, not exceeding 2.04% of the total share capital, due to personal funding needs [16] - Yikang Pharmaceutical is engaged in the production and sales of excipients, raw materials, finished drugs, and new energy materials [16] Group 11 - Sichuan Gold's shareholder plans to reduce holdings by up to 7.56 million shares, accounting for 1.80% of the total share capital [19] - Sichuan Gold focuses on the construction, mining, and sales of gold mines [19] Group 12 - Kangchen Pharmaceutical received approval for a clinical trial of an innovative drug for treating advanced esophageal squamous cell carcinoma [20][21] - Kangchen Pharmaceutical specializes in the manufacturing of chemical drug formulations [21] Group 13 - UCloud plans to repurchase shares worth between CNY 8 million and CNY 10 million for employee stock ownership plans [22] - UCloud provides cloud computing services centered on IT infrastructure [22] Group 14 - Woton Technology announced an adjustment to its share repurchase plan, raising the price cap to CNY 60 per share [24] - Woton Technology specializes in the research, manufacturing, and sales of separation membrane products [24] Group 15 - Five Continents Medical announced plans for shareholders to reduce holdings by up to 126,530 shares, accounting for 1.8606% of the total share capital [26] - Five Continents Medical focuses on the research, manufacturing, and sales of disposable sterile infusion medical devices [26] Group 16 - CIMC Group plans to repurchase A-shares with a total amount not exceeding CNY 5 billion [27] - CIMC Group specializes in logistics and energy equipment solutions [27] Group 17 - Zhifei Biological's subsidiary received a drug registration certificate for a trivalent influenza vaccine suitable for individuals aged 3 and above [29][30] - Zhifei Biological is involved in the research, development, production, and sales of vaccines and biological products [30]

Performance Forecasts - Yinglian Co., Ltd. expects a net profit growth of 1531.13% to 1672.97% year-on-year for the first three quarters [1] - Dalian Heavy Industry anticipates a net profit growth of 19.91% to 28.52% year-on-year for the first three quarters [1] Project Investments - Wharton Technology plans to invest in the enhancement of membrane materials and membrane components [1] - Jiufeng Energy intends to invest in a coal-to-natural gas project in Xinjiang [1] Contract Awards - Qiaoyin Co., Ltd. is pre-awarded a contract worth approximately 512 million yuan for integrated sanitation operations in Laishui County, Baoding City, Hebei Province [1] - Dash Smart signed a contract for a smart hospital project worth 113 million yuan [1] Equity Acquisitions - Conch New Materials plans to acquire 51% equity in North China Plastics [1] - Suochen Technology intends to acquire 60% equity in Likong Technology [1] - Jingye Intelligent plans to acquire 51% equity in Hefei Shengwen for 108 million yuan [1] - Landi Group plans to acquire 20.1667% equity in Jujia Technology for 121 million yuan [1] Share Buybacks - Hanshuo Technology plans to repurchase shares worth between 150 million yuan and 300 million yuan [2] - Youke De intends to spend between 8 million yuan and 10 million yuan on share buybacks [2] H-Shares - Jinghe Integrated Circuit has submitted an application for H-share issuance and listing on the Hong Kong Stock Exchange [2] - Lingyi Manufacturing is planning to issue H-shares and list on the Hong Kong Stock Exchange [2] - Changchun High-tech has submitted an application for the issuance of H-shares [2] Shareholding Changes - Senba Sensor's actual controller plans to reduce holdings by no more than 1.09% [3] - Erkang Pharmaceutical's controlling shareholder intends to reduce holdings by no more than 2.04% [3] - Andeli's BVI Donghua plans to reduce holdings by no more than 1.00% [3] - Zhiyang Innovation's controlling shareholder and its concerted actioner plan to reduce a total of no more than 4.225 million shares [3] - Xizi Clean Energy's chairman plans to increase holdings by 30 million to 50 million yuan [3] Other Activities - Luoxin Pharmaceutical plans to raise no more than 842 million yuan for innovative drug research and development projects [3] - Huaxin Xinchang has received project designation notification from Jiangqi Group [3] - Jinpu Garden plans to raise no more than 129 million yuan through a private placement to Nanjing Lisen [3]

Group 1 - The company, UCloud (688158), announced a share repurchase plan with a budget of 8 million to 10 million yuan [1] - The maximum repurchase price is set at 40.33 yuan per share [1]

Core Viewpoint - The company, UCloud, announced a share buyback plan with a total amount between 8 million and 10 million yuan, with a maximum buyback price of 40.33 yuan per share, which is 52.77% higher than the current price of 26.40 yuan, reflecting a significant increase in its stock price by 88.84% this year [1]. Group 1: Share Buyback Details - UCloud plans to repurchase shares through centralized bidding, with a buyback amount not less than 8 million yuan and not exceeding 10 million yuan [1]. - The buyback period is set for 6 months, and the funding will come from the company's own funds [1]. - Stock buybacks are generally viewed as a price stabilization measure, allowing companies to buy back their issued shares from the market [1]. Group 2: Financial Performance - As of June 30, UCloud reported a revenue of 791 million yuan for the first half of 2025, representing a year-on-year growth of 8.37% [2]. - The company recorded a net profit attributable to shareholders of -79.65 million yuan, which is a 26.56% increase compared to the previous period [2]. Group 3: Shareholder and Dividend Information - UCloud has cumulatively distributed dividends of 21.13 million yuan since its A-share listing, with no dividends paid in the last three years [3]. - As of June 30, 2025, the number of UCloud shareholders decreased by 2.53% to 40,200, while the average circulating shares per person increased by 3.42% to 10,083 shares [2]. - The top ten circulating shareholders include notable funds, with the 博时上证科创板人工智能ETF increasing its holdings by 1.34 million shares [3].

Core Viewpoint - The company, UCloud (688158.SH), announced a share repurchase plan with a budget of 8 million to 10 million yuan, with a maximum repurchase price of 40.33 yuan per share, intended for equity incentives or employee stock ownership plans [1] Group 1 - The total amount allocated for the share repurchase is between 8 million and 10 million yuan [1] - The maximum price for repurchasing shares is set at 40.33 yuan per share [1] - The purpose of the share repurchase is to support equity incentives or employee stock ownership plans [1]

Core Points - The company Youke De (688158.SH) has announced a draft for its 2025 restricted stock incentive plan, proposing to grant 1.82 million shares of restricted stock, which accounts for approximately 0.40% of the company's total share capital at the time of the announcement [1] - The initial grant will consist of 1.505 million shares, with 18 individuals being the recipients of this initial grant, and the grant price is set at 22 yuan per share [1]

Core Viewpoint - The company Youke De (688158.SH) has announced a draft for its 2025 restricted stock incentive plan, proposing to grant 1.82 million shares of restricted stock to incentive recipients, which represents approximately 0.40% of the company's total share capital at the time of the announcement [1] Summary by Categories Incentive Plan Details - The plan includes an initial grant of 1.505 million shares, with 18 recipients designated for this initial grant [1] - The grant price is set at 22 yuan per share [1]